HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Heart 2008;94:545-546; doi:10.1136/hrt.2007.133785
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Herrmann-Lingen, C.
Right arrow Articles by Pieske, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann-Lingen, C.
Right arrow Articles by Pieske, B.
Topic Collections
Right arrowRelevant Article

EDITORIALS

Natriuretic peptides or psychometric tests? Prognostic markers in congestive heart failure

Christoph Herrmann-Lingen1, Burkert Pieske2

1 Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen, Germany
2 Department of Cardiology, University Hospital of Graz, Austria

Correspondence to:
Professor Christoph Herrmann-Lingen, Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen, von-Siebold-Str. 5, Göttingen, D-37099, Germany; cherrma@gwdg.de

The first 150 words of the full text of this article appear below.

Congestive heart failure (CHF) is a highly prevalent condition and its impact will increase further in the future. Due to its poor prognosis, heart failure has been named a "malignant disease". Several prognostic factors have been identified in CHF patients. Comprehensive prognostic scores have been based on clinical and laboratory parameters such as age, gender, comorbidity, ejection fraction, exercise capacity or haemoglobin concentrations.1 These scores have, however, often ignored the prognostic potential of neuroendocrine markers in CHF. B-type natriuretic peptides seem to be the most powerful neuroendocrine markers and their routine application has found increasing support. Longitudinal studies have demonstrated independent statistical effects of BNP and NT-pro-BNP on mortality rates. In a systematic review, Doust et al2 found that in 23 of 35 multivariable analyses CHF outcomes were predicted by B-type natriuretic peptides at higher significance levels than by any other risk marker. In nine of these analyses, BNP or . . . [Full text of this article]


Relevant Article

Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure
J T Parissis, M Nikolaou, D Farmakis, V Bistola, I A Paraskevaidis, S Adamopoulos, G Filippatos, and D T Kremastinos
Heart 2008 94: 585-589. [Abstract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society